Fig. 3

Cumulative survival according to the pT3 subclassification based on the ELI. DFS: disease-free survival; OS: overall survival; LR: log-rank; a) b) There were no significant differences in DFS or OS between pT3a and pT3u patients. c) d) The DFS and OS rates of patients with pT3b disease were significantly lower than those of patients with pT3a disease, but they did not differ from those of patients with pT4a disease